Key result
POTS patients show a ~46 bpm orthostatic heart rate increase, exceeding healthy controls and PASC.
Why the study?
Postural orthostatic tachycardia syndrome is increasingly recognized following SARS-CoV-2 infection, prompting a comparison of autonomic phenotype, functional impact, and circulating immune markers across these conditions.
Cross-Sectional (n=67)
POTS and PASC share overlapping autonomic symptoms and functional impairment, with some cytokine alterations but no predictive utility for autoantibodies in POTS diagnosis.
Answers are grounded in this paper and cite their sources.
Distinguishes POTS by orthostatic tachycardia from PASC and controls; leaves open cytokine roles in diagnosis or management.
Background Postural orthostatic tachycardia syndrome (POTS) is increasingly recognized after SARS‐CoV‐2 infection. We compared autonomic phenotype, functional impact, and circulating immune markers in POTS, postacute sequelae of COVID‐19 (PASC), and healthy controls. Methods In this cross‐sectional study (August 2021 to December 2022), we recruited patients with POTS (n=24) or PASC (n=24) and healthy controls (n=19). Participants underwent 10‐minute active stand testing, 24‐hour Holter monitoring, serum cytokine, and adrenergic autoantibody assays (cell‐based activation). Patient‐reported outcome measures were collected via secure electronic link. Results The study included 67 participants (mean age, 32.4±8.9 years; 71% women). Compared with controls and participants with PASC, participants with POTS demonstrated significantly higher orthostatic tachycardia (active stand heart rate change from supine to standing, 46.3±14.0 bpm versus 12.7±6.6 bpm in controls and 34.6±13.7 bpm in PASC; P <0.001; POTS versus PASC P =0.005). Among participants with PASC, 62.5% met formal POTS criteria. Cytokine analysis revealed lower interleukin‐2 and higher interleukin‐8 levels in POTS versus controls, with POTS cases showing elevated tumor necrosis factor‐α compared with those without POTS. Autoantibody activation measures did not differ significantly among groups, and multivariate biomarker models lacked predictive utility for POTS diagnosis. Patient‐reported outcome measures indicated greater fatigue, orthostatic intolerance, and autonomic symptom burden and reduced health‐related quality of life in POTS and PASC groups compared with controls. Conclusions POTS and PASC exhibit overlapping autonomic symptomology and profound functional impairment. Alterations in cytokines suggest a possible cytokine‐linked or compartmentalized immune contribution, but cytokine and autoantibody measures alone do not predict POTS. Routine autonomic assessment in persistent postviral illness and larger longitudinal, multimodal studies are warranted. Registration Australian New Zealand Clinical Trial Registry; ACTRN: 12621000476831.
No takes yet. Share an insight, caveat, or question.
Seeley et al. (2026) conducted a cross-sectional in Postural orthostatic tachycardia syndrome (POTS) and postacute sequelae of SARS-CoV-2 (PASC) (n=67). POTS and PASC vs. Healthy controls was evaluated on Active stand heart rate change from supine to standing (p=<0.001). Patients with POTS demonstrated higher orthostatic tachycardia compared with healthy controls and PASC.
Synapse has enriched 10 related papers. Consider them for comparative context: